Targeting of drugs and nanoparticles to tumors

The various types of cells that comprise the tumor mass all carry molecular markers that are not expressed or are expressed at much lower levels in normal cells. These differentially expressed molecules can be used as docking sites to concentrate drug conjugates and nanoparticles at tumors. Specific...

Full description

Bibliographic Details
Main Authors: Ruoslahti, Erkki (Author), Sailor, Michael J. (Author), Bhatia, Sangeeta N. (Contributor)
Other Authors: Whitaker College of Health Sciences and Technology (Contributor), Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science (Contributor)
Format: Article
Language:English
Published: Rockefeller University Press, 2010-09-24T14:59:44Z.
Subjects:
Online Access:Get fulltext
LEADER 02095 am a22003013u 4500
001 58699
042 |a dc 
100 1 0 |a Ruoslahti, Erkki  |e author 
100 1 0 |a Whitaker College of Health Sciences and Technology  |e contributor 
100 1 0 |a Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science  |e contributor 
100 1 0 |a Bhatia, Sangeeta N.  |e contributor 
100 1 0 |a Bhatia, Sangeeta N.  |e contributor 
700 1 0 |a Sailor, Michael J.  |e author 
700 1 0 |a Bhatia, Sangeeta N.  |e author 
245 0 0 |a Targeting of drugs and nanoparticles to tumors 
260 |b Rockefeller University Press,   |c 2010-09-24T14:59:44Z. 
856 |z Get fulltext  |u http://hdl.handle.net/1721.1/58699 
520 |a The various types of cells that comprise the tumor mass all carry molecular markers that are not expressed or are expressed at much lower levels in normal cells. These differentially expressed molecules can be used as docking sites to concentrate drug conjugates and nanoparticles at tumors. Specific markers in tumor vessels are particularly well suited for targeting because molecules at the surface of blood vessels are readily accessible to circulating compounds. The increased concentration of a drug in the site of disease made possible by targeted delivery can be used to increase efficacy, reduce side effects, or achieve some of both. We review the recent advances in this delivery approach with a focus on the use of molecular markers of tumor vasculature as the primary target and nanoparticles as the delivery vehicle. 
520 |a United States. Dept. of Defense (grant W81XWH-08-1-0727) 
520 |a National Science Foundation (grant DMR-0806859) 
520 |a Moores Cancer Center 
520 |a NanoTUMOR Center 
520 |a National Institutes of Health (U.S.) (grant U54 CA-119335) 
520 |a MIT/Harvard Center for Cancer Nanotechnology (grant U54 CA-119349) 
520 |a National Cancer Institute (U.S.). Bioengineering Research Partnership (grant CA-122427) 
546 |a en_US 
655 7 |a Article 
773 |t Journal of Cell Biology